23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Nordic
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Nykode raises NOK 286m to accelerate drug development

Norwegian biotech company Nykode Therapeutics has completed a private placement of approximately NOK 286m before costs.
Advertisement

The offering was several times oversubscribed, with strong interest from both Norwegian and international investors. Rasmussengruppen, which is associated with board member Trygve Lauvdal, was allocated 7.2 million shares. Norda and Victoria India Fund, both associated with board member Christian Åbyholm, were each allocated approximately 1.7 million shares.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.078|